Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.55 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.55 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.55 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | AURKA | O14965 | 2/20 | 0.55 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.55 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.55 |
| ▸ | PAK4 | O96013 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 1/20 | 0.55 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | FYN | P06241 | 1/20 | 0.55 |
| ▸ | CSF1R | P07333 | 1/20 | 0.55 |
| ▸ | RET | P07949 | 1/20 | 0.55 |
| ▸ | MET | P08581 | 1/20 | 0.55 |
| ▸ | PIM1 | P11309 | 1/20 | 0.55 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5758921 | 0.89 | IDH1 (0.50) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5757748 | 0.88 | ALK (0.60) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5759931 | 0.88 | ROCK1 (0.49) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5759792 | 0.88 | KDR (0.49) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5760381 | 0.88 | KDR (0.51) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5759796 | 0.87 | ROCK1 (0.52) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL23788214 | 0.86 | TUBB4A (0.50) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5758488 | 0.86 | ALK (0.73) | KDRCDK5PDGFRBALKPDGFRA | |
| Aniline SCHEMBL5760269 | 0.84 | KDR (0.48) | KDRCDK5PDGFRBALKPDGFRA | |
| SCHEMBL5760681 | 0.84 | KDR (0.48) | KDRCDK5PDGFRBALKPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | claimed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | claimed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | claimed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | claimed |
| US-7101869-B2 | 2,4-diaminopyrimidine compounds useful as immunosuppressants | PFIZER INC. (US) | 2006-09-05 | — | — | US | disclosed |
| EP-1242403-B1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PROD INC (US) | 2006-01-04 | — | — | EP | disclosed |
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | BLUMENKOPF TODD A (US) | 2003-10-09 | — | — | US | disclosed |
| EP-1242403-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | Pfizer Products Inc. (US) | 2002-09-25 | — | — | EP | disclosed |
| WO-2001040215-A1 | 2,4-DIAMINOPYRIMIDINE COMPOUNDS USFUL AS IMMUNOSUPPRESSANTS | PFIZER PRODUCTS INC. (US) | 2001-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191307-A1 | 2,4-Diaminopyrimidine compounds useful as immunosuppressants | CCR1, AOC1, NOD1 | KDR 4735/4885CDK5 1932/4885PDGFRB 4303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.